Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ACADIA Pharmaceuticals Inc ACAD

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders... see more

Bullboard (NDAQ:ACAD)

View:
User Avatar Image
(280)
•••
  • whytestocksX
Post by whytestockson Aug 07, 2024 7:00pm

Acadia Pharmaceuticals to Participate in the Canaccord Genui

Breaking News: $ACAD Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth ConferenceAcadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in ...more  
User Avatar Image
(4)
•••
  • AviseAnalyticsX
Post by AviseAnalyticson Jun 22, 2022 7:27am

ACADIA PHARMACEUTICALS: WHAT’S NEXT AFTER THE NEGATIVE FDA A

$ACAD Acadia Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company developing small molecule drugs for treating central nervous system disorders, faced a setback at the FDA's ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities